Nurix Therapeutics Inc. (NRIX) News
Filter NRIX News Items
NRIX News Results
|Loading, please wait...|
NRIX News Highlights
- For NRIX, its 30 day story count is now at 2.
- Over the past 8 days, the trend for NRIX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about NRIX are CIO, LINK and NU.
Latest NRIX News From Around the Web
Below are the latest news stories about Nurix Therapeutics Inc that investors may wish to consider to help them evaluate NRIX as an investment opportunity.
In this article, we discuss the 10 new stocks that Cathie Wood added to her portfolio in Q4 2021. You can skip our comprehensive analysis of ARK Investment Management’s investment strategy, and go directly to Cathie Wood’s Latest Portfolio: 5 New Stock Picks. Cathie Wood is the CEO, CIO, and founder of ARK Investment Management. Starting […]
Nurix Therapeutics Announces Participation in the 11th Annual SVB Leerink Global Healthcare Conference
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 3:40 PM ET. The event will be webcast live and may be accessed via a link in the Investors section of the Nu
In a report released today, Zhiqiang Shu from Berenberg Bank maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $48.00. The company's shares closed last Thursday at $17.29, close to its 52-week low of $17.10. According to TipRanks.com, Shu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -25.9% and a 14.4% success rate. Shu covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Monte Rosa Therapeutics, and Sensei Biotherapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Nurix Therapeutics with a $51.
In a report released today, Gil Blum from Needham maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $48.00. The company's shares closed last Thursday at $17.29, close to its 52-week low of $17.10. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -44.3% and a 5.5% success rate. Blum covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Rocket Pharmaceuticals, and Crispr Therapeutics AG. Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $49.75, implying a 168.
Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Corporate Update
Advanced four wholly owned and internally developed programs into clinical development Strengthened balance sheet with year-end cash and investments totaling $433 million Anticipate multiple clinical milestones in 2022 SAN FRANCISCO, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today reported financial results for the fourth quarter and fiscal year ended November 30, 2021 and pr
The nature of investing is that you win some, and you lose some. Anyone who held Nurix Therapeutics, Inc. ( NASDAQ:NRIX...
No summary available.
Investment company Mass General Brigham, Inc (Current Portfolio) buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Airbnb Inc, sells iShares Core S&P 500 ETF, iShares Core U.S.
Nurix leads protein modulation field with four active clinical stage programs Anticipates data-rich 2022 with clinical-stage programs and a pipeline fueled by proprietary DELigase platform SAN FRANCISCO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today outlined key objectives and anticipated milestones for 2022 and provided an overview of recent progress. “2021 was a significant and highly p